Impact of a 5-Day Expedition to Machu Picchu on Persons with Multiple Sclerosis

Table 2

Baseline characteristics of the participants (𝑛=9).

Female number (%)	6 (66%)
Relapsing onset (%)	9 (100%)
Age at trekking, year
Median (range)	42 (28–49)
Age at onset of MS, year
Median (range)	30 (23–40)
Disease duration, year
Median (range)	9 (3–24)
EDSS
Median (range)	3 (1–4)
Annualized relapse rate	0.80
Current treatment
Interferon beta or glatiramer acetate	3 (2M 1F)
Natalizumab or alemtuzumab	2 (2F)
No immunomodulatory treatment	4 (1M 3F)
Comorbidity (rheumatoid arthritis, narcolepsy)	2 (2F)
Cardiovascular risk factors (smoking, obesity)*	4/9 (2M, 2F)

∗Three of them had reached EDSS 4.